Idexx Laboratories (IDXX) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $547.18, +3.43% vs the prior close of $529.01.
- Volume 545.30K shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
IDXX jumps 3.4% to $547.18, a 1-month high. Closed at $547.18, +3.43% vs the prior close of $529.01. Day range $535.29–$547.83, opened at $538.34.
IDXX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — IDXX jumps 3.4% to $547.18, a 1-month high
- Closed at $547.18, +3.43% vs the prior close of $529.01. Day range $535.29–$547.83, opened at $538.34.
- Volume was 545.30K shares, 1.0x its 50-day average of 523.64K.
- Price is +2.1% vs its 50-day average ($535.84) and -5.7% vs its 200-day average ($580.28).
- 52-week range $500.61–$769.98; today's close sits at 17% of that range, 28.9% below the 52-week high.
Oct 14, 2026 — IDXX rises 1.7% to $529.01
- Closed at $529.01, +1.67% vs the prior close of $520.31. Day range $518.84–$529.63, opened at $520.20.
- Volume was 824.40K shares, 1.5x its 50-day average of 538.39K.
- Price is -1.4% vs its 50-day average ($536.59) and -8.9% vs its 200-day average ($580.98).
- 52-week range $500.61–$769.98; today's close sits at 11% of that range, 31.3% below the 52-week high.
Oct 13, 2026 — IDXX dips 0.7% to $520.31
- Closed at $520.31, -0.69% vs the prior close of $523.94. Day range $514.73–$528.49, opened at $525.73.
- Volume was 445.40K shares, 0.8x its 50-day average of 553.65K.
- Price is -3.2% vs its 50-day average ($537.78) and -10.6% vs its 200-day average ($581.78).
- 52-week range $500.61–$769.98; today's close sits at 7% of that range, 32.4% below the 52-week high.
Oct 12, 2026 — IDXX rises 1.1% to $523.94, 3 up days in a row
- Closed at $523.94, +1.15% vs the prior close of $518.00. Day range $515.13–$525.76, opened at $518.00.
- Volume was 552.80K shares, 1.0x its 50-day average of 555.21K.
- Price is -2.7% vs its 50-day average ($538.73) and -10.1% vs its 200-day average ($582.62).
- 52-week range $500.61–$769.98; today's close sits at 9% of that range, 32.0% below the 52-week high.
- That makes 3 straight gains.
Oct 9, 2026 — IDXX rises 0.9% to $518.00
- Closed at $518.00, +0.95% vs the prior close of $513.14. Day range $513.10–$522.02, opened at $513.67.
- Volume was 466.80K shares, 0.8x its 50-day average of 556.14K.
- Price is -4.0% vs its 50-day average ($539.43) and -11.2% vs its 200-day average ($583.41).
- 52-week range $500.61–$769.98; today's close sits at 6% of that range, 32.7% below the 52-week high.
Oct 8, 2026 — IDXX rises 1.3% to $513.14
- Closed at $513.14, +1.28% vs the prior close of $506.67. Day range $506.12–$514.51, opened at $506.67.
- Volume was 696.70K shares, 1.3x its 50-day average of 551.31K.
- Price is -5.0% vs its 50-day average ($540.25) and -12.2% vs its 200-day average ($584.33).
- 52-week range $500.61–$769.98; today's close sits at 5% of that range, 33.4% below the 52-week high.
Oct 7, 2026 — IDXX dips 1.7% to $506.67
- Closed at $506.67, -1.70% vs the prior close of $515.41. Day range $501.17–$515.17, opened at $513.31.
- Volume was 716.40K shares, 1.3x its 50-day average of 545.90K.
- Price is -6.4% vs its 50-day average ($541.38) and -13.4% vs its 200-day average ($585.27).
- 52-week range $500.61–$769.98; today's close sits at 2% of that range, 34.2% below the 52-week high.
Oct 6, 2026 — IDXX dips 2.2% to $515.41
- Closed at $515.41, -2.21% vs the prior close of $527.07. Day range $512.54–$531.38, opened at $529.14.
- Volume was 502.40K shares, 0.9x its 50-day average of 546.11K.
- Price is -5.0% vs its 50-day average ($542.64) and -12.1% vs its 200-day average ($586.22).
- 52-week range $500.61–$769.98; today's close sits at 5% of that range, 33.1% below the 52-week high.
Oct 5, 2026 — IDXX rises 1.7% to $527.07
- Closed at $527.07, +1.67% vs the prior close of $518.39. Day range $513.48–$528.69, opened at $516.57.
- Volume was 588.90K shares, 1.1x its 50-day average of 543.08K.
- Price is -3.0% vs its 50-day average ($543.45) and -10.2% vs its 200-day average ($587.12).
- 52-week range $500.61–$769.98; today's close sits at 10% of that range, 31.5% below the 52-week high.
Oct 2, 2026 — IDXX ends flat (+0.1%) to $518.39
- Closed at $518.39, +0.12% vs the prior close of $517.75. Day range $516.02–$524.02, opened at $523.50.
- Volume was 288.80K shares, 0.5x its 50-day average of 546.49K — lighter than usual.
- Price is -4.7% vs its 50-day average ($543.80) and -11.8% vs its 200-day average ($587.95).
- 52-week range $500.61–$769.98; today's close sits at 7% of that range, 32.7% below the 52-week high.
IDXX latest news & SEC filings
Every SEC filing by or about IDXX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kingsley Lawrence D sold 2,203 shares at $532.08 (≈$1.17M) on Sep 4, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 4, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 4, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $1.22B (prior year $1.11B) (+9.7% vs Jun 30, 2025)
- Net income: $338.41M (prior year $293.99M) (+15.1% vs Jun 30, 2025)
- Diluted EPS: $4.27 (prior year $3.63) (+17.6% vs Jun 30, 2025)
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade IDXX
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Feb 2, 2026, Nov 3, 2025. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.32% (largest 3.4%).
- Liquidity: about 531.43K shares (≈$290.79M) trade per day on average.
- 52-week position: $547.18 vs a range of $500.61–$769.98 (17% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Lawrence D Kingsley sold 2,203 shares on Sep 4, 2026.
- Latest filings: 10-Q Aug 4, 2026; 8-K Aug 4, 2026; 8-K May 15, 2026.
- Share count: 78.78M shares outstanding (Jul 31, 2026), -1.5% vs a year earlier.
- Listing: Nasdaq · industry: In Vitro & In Vivo Diagnostic Substances.
IDXX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 538.34 | 547.83 | 535.29 | 547.18 | 545.30K |
| Oct 14, 2026 | 520.20 | 529.63 | 518.84 | 529.01 | 824.40K |
| Oct 13, 2026 | 525.73 | 528.49 | 514.73 | 520.31 | 445.40K |
| Oct 12, 2026 | 518.00 | 525.76 | 515.13 | 523.94 | 552.80K |
| Oct 9, 2026 | 513.67 | 522.02 | 513.10 | 518.00 | 466.80K |
| Oct 8, 2026 | 506.67 | 514.51 | 506.12 | 513.14 | 696.70K |
| Oct 7, 2026 | 513.31 | 515.17 | 501.17 | 506.67 | 716.40K |
| Oct 6, 2026 | 529.14 | 531.38 | 512.54 | 515.41 | 502.40K |
| Oct 5, 2026 | 516.57 | 528.69 | 513.48 | 527.07 | 588.90K |
| Oct 2, 2026 | 523.50 | 524.02 | 516.02 | 518.39 | 288.80K |
| Oct 1, 2026 | 521.58 | 525.96 | 517.06 | 517.75 | 320.30K |
| Sep 30, 2026 | 531.09 | 531.11 | 521.78 | 522.19 | 502.20K |
| Sep 29, 2026 | 530.10 | 536.84 | 522.11 | 533.44 | 648.90K |
| Sep 28, 2026 | 516.53 | 530.15 | 515.12 | 529.06 | 392.00K |
| Sep 25, 2026 | 510.94 | 520.16 | 507.01 | 519.26 | 331.10K |
| Sep 24, 2026 | 520.88 | 524.12 | 511.73 | 513.39 | 328.30K |
| Sep 23, 2026 | 517.20 | 523.22 | 516.88 | 522.02 | 364.20K |
| Sep 22, 2026 | 519.27 | 523.95 | 511.73 | 521.50 | 476.50K |
| Sep 21, 2026 | 511.65 | 518.96 | 506.22 | 515.30 | 513.20K |
| Sep 18, 2026 | 506.48 | 516.43 | 505.21 | 511.65 | 1.12M |
About Idexx Laboratories
Idexx Laboratories (IDXX) is listed on the Nasdaq and classified by the SEC under “In Vitro & In Vivo Diagnostic Substances”. Its business address is in WESTBROOK, ME. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 874716.
IDXX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Irene Chang Britt | Director | May 14, 2026 |
| Bruce L. Claflin | Director | May 14, 2026 |
| Stuart Essig | Director | May 14, 2026 |
| Joseph L Hooley | Director | Aug 3, 2026 |
| Daniel M Junius | Director | May 14, 2026 |
| Lawrence D Kingsley | Director | Sep 9, 2026 |
| Jonathan Jay Mazelsky | President and CEO | Mar 2, 2026 |
| Karen Peacock | Director | May 14, 2026 |
| Sam Samad | Director | May 14, 2026 |
| M Anne Szostak | Director | May 11, 2026 |
| Sophie V. Vandebroek | Director | May 14, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Andrew Emerson | EVP, CFO and Treasurer | Aug 24, 2026 |
| Michael G Erickson | Executive Vice President | Mar 3, 2026 |
| George Fennell | Executive Vice President | Jun 2, 2026 |
| Nimrata Hunt | Executive Vice President | Mar 5, 2026 |
| Michael Perkins Johnson | Executive Vice President | Feb 17, 2026 |
| Michael Lane | Executive Vice President | Feb 17, 2026 |
| Jonathan Jay Mazelsky | President and CEO | Mar 2, 2026 |
| Michael Schreck | Executive Vice President | Feb 17, 2026 |
| Martin Alexander Smith | Executive Vice President | Feb 17, 2026 |
| Sharon E. Underberg | EVP, GC & Corporate Secretary | Mar 5, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 4, 2026 | Lawrence D Kingsley | Sale | 2,203 | $532.08 |
| Mar 3, 2026 | Nimrata Hunt | Sale | 1,758 | $634.57 |
| Feb 26, 2026 | Nimrata Hunt | Sale | 2,693 | $661.54 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | Sale | 2,860 | $657.84 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | Sale | 1,095 | $651.49 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | Sale | 1,281 | $650.67 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | Sale | 2,589 | $663.04 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | Sale | 1,000 | $662.16 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | Sale | 1,200 | $661.10 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | Sale | 2,859 | $659.75 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | Sale | 1,669 | $652.49 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | Sale | 1,171 | $653.68 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | Sale | 1,111 | $654.63 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | Sale | 1,488 | $655.85 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | Sale | 1,343 | $656.85 |
IDXX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $4.30B | $1.06B | 13.08 | $1.18B |
| Dec 31, 2024 | $3.90B | $887.87M | 10.67 | $929.00M |
| Dec 31, 2023 | $3.66B | $845.04M | 10.06 | $906.51M |
| Dec 31, 2022 | $3.37B | $679.09M | 8.03 | $542.98M |
| Dec 31, 2021 | $3.22B | $744.85M | 8.60 | $755.55M |
Latest balance sheet: total assets $3.44B, total liabilities $1.83B, cash $196.93M (as of Jun 30, 2026).
IDXX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $588.09 |
| May 5, 2026 | 8-K Item 2.02 (results) | $562.97 |
| Feb 2, 2026 | 8-K Item 2.02 (results) | $639.60 |
| Nov 3, 2025 | 8-K Item 2.02 (results) | $722.94 |
| Aug 4, 2025 | 8-K Item 2.02 (results) | $682.78 |
| May 1, 2025 | 8-K Item 2.02 (results) | $471.38 |
| Feb 3, 2025 | 8-K Item 2.02 (results) | $469.04 |
| Oct 31, 2024 | 8-K Item 2.02 (results) | $406.92 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 1, 2024 | 8-K Item 2.02 (results) | — |
| Feb 5, 2024 | 8-K Item 2.02 (results) | — |
| Nov 1, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · In Vitro & In Vivo Diagnostic Substances
Lantheus (LNTH)Intellia Therapeutics (NTLA)Neogen (NEOG)Celldex Therapeutics (CLDX)QuidelOrtho (QDEL)Achieve Life Sciences (ACHV)Myriad Genetics (MYGN)Alpha Teknova (TKNO)Insight Molecular Diagnostics (IMDX)Volitionrx (VNRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on IDXX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.